Novo Nordisk and Eli Lilly's Groundbreaking GLP-1 Updates and Market Shifts
In this episode of Downsized News, hosts Laraine and Christopher Durham discuss the latest developments in the world of GLP-1 treatments for obesity and type 2 diabetes. They cover major headlines including Eli Lilly's launch of Mounjaro in India, Novo Nordisk's acquisition of a new triple agonist obesity drug, and a breakthrough MIT study on in vivo antibody painting that could revolutionize GLP-1 drug delivery. The episode also highlights the USDA recall of Chomps beef sticks due to metal contamination, Novo Nordisk's partnership to develop UBT 2-51, and the expansion of Wegovy's savings program. Additionally, the hosts delve into the controversy surrounding the FDA and compounding pharmacies, as well as promising early results from Allurion’s GLP-1 and weight loss balloon combination therapy. The episode wraps up with calls for affordable pricing and better patient access to these crucial medications.
DOWNSIZED GLP-1 COMPANION PRODUCT STORE: https://thedownsized.org/downsized-store
BOOK THE DOWNSIZED AT SEA CRUISE: https://thedownsized.org/downsized-at...
DOWNSIZED WEBSITE: https://thedownsized.org/
JOIN CLUB DOWNSIZED: / @thedownsized
FOR SPONSORSHIPS, BRAND DEALS & COLLABS: https://thedownsized.org/contact/
00:00 Introduction and Overview
01:23 Mounjaro Launches in India
04:04 Chomps Beef Sticks Recall
06:12 Novo Nordisk's New Triple Agonist Drug
10:03 MIT's Antibody Painting Research
13:44 FDA Crackdown on Compounding Pharmacies
16:00 Allion Balloon and Semaglutide Study
18:51 Wegovy Savings Program Expansion
21:56 Conclusion and Sign-Off